Lipid Management in Patients Who Have HIV and Are Receiving HIV Therapy

This publication has 54 references indexed in Scilit:

• Fish Oil and Fenofibrate for the Treatment of Hypertriglyceridemia in HIV-Infected Subjects on Antiretroviral Therapy
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2008
• Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration
  The Lancet, 2008
• Raltegravir
  Drugs, 2008
• Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV
  Lipids in Health and Disease, 2007
• Class of Antiretroviral Drugs and the Risk of Myocardial Infarction
  New England Journal of Medicine, 2007
• The use of the Framingham equation to predict myocardial infarctions in HIV‐infected patients: comparison with observed events in the D:A:D Study
  HIV Medicine, 2006
• Associations among Race/Ethnicity, ApoC-III Genotypes, and Lipids in HIV-1-Infected Individuals on Antiretroviral Therapy
  PLoS Medicine, 2006
• A prospective, 96-week study of the impact of TrizivirR, CombivirR/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity
  HIV Medicine, 2006
• Modeling the Influence ofAPOC3, APOE,andTNFPolymorphisms on the Risk of Antiretroviral Therapy–Associated Lipid Disorders
  The Journal of Infectious Diseases, 2005
• Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized Trial
  JAMA, 2004